Who is a good candidate for R-CHOP treatment?

Ideal candidates are patients with newly diagnosed, CD20-positive diffuse large B-cell lymphoma, which is the most common subtype of non-Hodgkin lymphoma. Contraindications include severe heart conditions (due to doxorubicin’s cardiac toxicity), active infections, or significantly impaired liver or kidney function. A thorough pre-treatment evaluation, including blood tests and cardiac imaging, is required to confirm suitability.